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Context: Steroidogenic factor-1 (SF-1, NR5A1, Ad4BP) is a master regulator of adrenal devel-
opment and steroidogenesis. Defects in several known targets of SF-1 can cause adrenal dis-
orders in humans.
Objective:Weaimed to identify novel targets of SF-1 in the human adrenal. These factors could be
important regulators of adrenal development and steroidogenesis and potential candidates for
adrenal dysfunction.
Design: A gene discovery strategy was developed based on bidirectional manipulation of SF-1.
OverexpressionorknockdownofSF-1 inNCI-H295Rhumanadrenocortical cellswasused to identify
a subset of positively-regulated SF-1 targets.
Results:This approach identifiedwell-established SF-1 target genes (STAR,CYP11A) and several
novel genes (VSNL1, ZIM2, PEG3, SOAT1, andMTSS1). Given its role in cholesterol metabolism,
sterol O-acyltransferase 1 (SOAT1, previously referred to as acyl-Coenzyme A:cholesterol acyl-
transferase 1, ACAT) was studied further and found to be expressed in the developing human
fetal adrenal cortex. We hypothesized that impaired SOAT1 activity could result in adrenal
insufficiency through reduced cholesteryl ester reserves or through toxic destruction of the
adrenal cells during development. Therefore, mutational analysis of SOAT1 in a cohort of 43
patients with unexplained adrenal insufficiency was performed but failed to reveal significant
coding sequence changes.
Conclusions: Our reverse discovery approach led to the identification of novel SF-1 targets and
defined SOAT1 as an important factor in human adrenal steroidogenesis. SF-1–dependent up-
regulation of SOAT1 may be important for maintaining readily-releasable cholesterol reserves
needed for active steroidogenesis andduring episodes of recurrent stress. (J Clin EndocrinolMetab
96: E663–E668, 2011)
Steroidogenic factor-1 (SF-1, NR5A1, Ad4BP) is akey transcriptional regulator of many aspects of
adrenal and reproductive development, steroidogene-
sis, and metabolism (1). More than 30 SF-1 responsive
genes have been identified, most of which play central
roles in adrenal and/or reproductive function (2). Here,
we describe a reverse discovery approach in an attempt
to identify novel SF-1 targets, which we hypothesize
could be important regulators of endocrine development
and steroidogenesis. Using an experimental strategy
based on bidirectional manipulation of SF-1 through
overexpression or knockdown in a human adrenal cell
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line we have identified a subset of positively regu-
lated SF-1 targets and investigated the potential role of
one of these genes as a cause of adrenal insufficiency in
humans.
Materials and Methods
Experimental design for bidirectional manipulation
of SF-1
A strategy was devised to transiently coexpress green flu-
orescent protein (GFP) and either SF-1 cDNA (“overexpres-
sion”) or SF-1–specific small hairpin RNA (shRNA) (“knock-
down”) in NCI-H295R human adrenocortical cells to allow
enrichment for successfully transfected and viable cells
through fluorescence-activated cell sorting (FACS) (overview
of strategy in Supplemental Methods, published on The
Endocrine Society’s Journals Online web site at http://
jcem.endojournals.org/). SF-1 overexpression was performed
using the full-length coding sequence of wild-type (WT) hu-
man SF-1 cloned into a pIRES2-AcGFP1-Nuc vector (Clon-
tech-Takara Bio Europe, Saint-Germain-en-Laye, France).
TheG35Emutation that impairs SF-1DNA-binding and func-
tion in vivo (3) and in vitro (4) was used as experimental
control. SF-1 knockdown was performed using the SureSi-
lencing shRNA Plasmid for Human NR5A1 with GFP marker
kit (KH05887G, SABiosciences, Frederick, MD), which in-
cludes a mismatch control.
Transfection and FACS
Plasmids (10g per 5 106 cells) were transfected intoNCI-
H295R cells using Amaxa Nucleofector II (Lonza Cologne AG,
Cologne, Germany), Nucleofector kit R, and program T-020.
Forty-eight hours after transfection, cells were harvested, pre-
pared, and submitted to FACS in aMoFloXDP sorter (Beckman
Coulter, High Wycombe, UK) (protocol available on request).
Viable GFP-expressing cells were either frozen to 80 C for
protein analysis or pooled and resuspended in TRIzol reagent
(Invitrogen, Paisley, UK) for RNA extraction.
Microarray analysis
Quality control of extracted RNA was performed with the
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Samples were processed using the Affymetrix GeneChip WT
Sense Target Labeling kit (Affymetrix, High Wycombe, UK)
according tomanufacturer’s instructions, startingwith 200 ng
total RNA. Four independent overexpression experiments
and five independent knockdown experiments were performed
and samples of labeled fragmented cDNA were hybridized to
GeneChip Human Gene 1.0 ST Arrays (Affymetrix). Based on
quality control of array data (R/Bioconductor and Partek
Genomics Suite), two overexpression arrays (paired SF-1 WT
and control) and one knockdown array (mismatch control) were
excluded. Differential gene expression analysis was performed
using the limmapackage inR/Bioconductor.ABenjamini-Hoch-
berg-corrected P value cut-off of 0.05 was used to select signif-
icant differentially expressed genes.
Validation by immunoblotting and quantitative
RT-PCR (qRT-PCR)
SF-1 expression in transfected cells was assessed by immu-
noblot (Western) analyses with an anti-SF-1 antibody (07-618;
UpstateMillipore,Watford, UK).Optical densities of blots were
quantified, normalized by -actin expression (antibody AC-15,
ab6276; Abcam, Cambridge, UK), and graphically represented
in relation to basal/control.
SF-1–dependent changes in transcript levels of target genes
were assessed by qRT-PCR. First-strand cDNAwas generated
using SuperScript II reverse transcriptase (Invitrogen) and
quantitative PCRperformed in aDNAEngineOpticon 2Real-
Time PCR System (Bio-Rad, Hemel Hempstead, UK) using
RT2 SYBR Green Master Mix and qPCR Primer Assays for
steroidogenic acute regulatory protein (STAR), CYP11A1,
SOAT1, and B2M (-2 microglobulin, endogenous control)
(all SABiosciences). Data were analyzed using the 2CT
method (5).
Confirmation of SF-1 responsiveness of novel
targets
Based on analysis for putative SF-1–binding sites (MatIn-
spector, www.genomatix.de) (6), the 1.0-kb, 4.8-kb, and
1.7-kb upstream sequences of VSNL1, SOAT1, and MTSS1,
respectively, were PCR amplified and individually cloned into
the pGL4.10[luc2] luciferase reporter (Promega, Southamp-
ton, UK). Expression vectors (pCMX) containing SF-1 [WT
and mutant G35E (Mut)] cDNAs and our protocol for tran-
sient gene expression assays in NCI-H295R cells have been
described previously (7).
Detection of sterol O-acyltransferase 1 (SOAT1) in
human fetal adrenal glands
Human fetal adrenal tissue from 6 to 9 weeks postconcep-
tion (wpc) and control tissue (heart; 8 wpc) were provided by
the Medical Research Council/Wellcome Trust–funded Hu-
man Developmental Biology Resource with Research Ethics
Committee approval and informed consent. Expression of
SOAT1 transcript was assessed by qRT-PCR using the
StepOnePlus Real-time PCR System, TaqMan Gene Expres-
sion Assays for human SOAT1 (Hs00162077_m1), and hu-
man glyceraldehyde-3-phosphate dehydrogenase as endogenous
control (4333764T; all Applied Biosystems, Warrington, UK).
Data were analyzed with StepOne software v2.1.
Immunofluorescence
Four-micron sections of adrenal tissue were incubated
overnightwithmouse polyclonal antihuman SOAT1 antibody
(H00006646-B01, Abnova, Taiwan; 1:400 dilution). Alexa
Fluor 555 antimouse IgG antibody (Invitrogen) was used for
detection. Images were collected on Zeiss Axiophot and 710
confocal microscopes (Carl Zeiss, Hertfordshire, UK).
Mutational analysis
After institutional board approval and with informed con-
sent, direct sequencing of the entire coding region of SOAT1
(NM_003101.4) was undertaken in a cohort of 43 patients
with adrenal insufficiency of unknown etiology, with or with-
out associated features (patients characteristics and amplifi-
cation/sequencing protocols provided in Supplemental Meth-
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ods). The Human Random Control-1
British Caucasian DNA Panel (Health
Protection Agency Culture Collections,
UK)was used for the analysis of previously un-
reported nonsynonymous changes.
Results
Validation of the experimental
strategy
Before microarray analysis, the abil-
ity of overexpression or knockdown of
SF-1 to identify known target geneswas
assessed using thewell-established SF-1
regulated genes STAR and CYP11A1
(P450 side-chain cleavage enzyme) (2).
Overexpression of SF-1 resulted in in-
creased SF-1 protein at 48 h and in-
creased STAR and CYP11A1 mRNA
(Fig. 1A). Principal component analysis
showed distinct differences in the
genomic profiles resultant from SF-1
overexpression compared with control
samples (Fig. 1A). In contrast, knock-
down of SF-1 (NR5A1) using shRNA
(Fig. 1B) resulted in decreased SF-1 pro-
tein, reduced STAR and CYP11A1
mRNA, and altered genomic profiles.
Thus, this bidirectional strategy to ma-
nipulate SF-1 appeared robust.
Identification of SF-1 targets
Overexpression of SF-1 resulted
in significant up-regulation of 570
genes (P 0.05, Benjamini-Hochberg
correction for multiple comparisons)
(Supplemental Table 1, A and B).
Knockdown of SF-1 using shRNA re-
sulted in significant down-regulation of
23 genes (P  0.05, Benjamini-Hoch-
berg correction) (Supplemental Table
2). Overlap of these datasets identified
seven positively regulated genes at six
loci (CYP11A1,VSNL1, STAR,ZIM2/
PEG3, SOAT1, andMTSS1) (Fig. 1C)
as well as fifteen negatively regulated
genes at fourteen loci (Supplemental
Table 3). SF-1 responsiveness of VSNL1,
SOAT1, andMTSS1was confirmed by
in silico analysis of SF-1–binding sites
within the promoters of these genes
[VSNL1 (1.0 kb), SOAT1 (4.8 kb) and
MTSS1 (1.7 kb)] as well as by showing
FIG. 1. Bidirectional manipulation of SF-1 in NCI-H295R adrenocortical cells. A, Transient
overexpression of wild-type (WT) SF-1 (over) induced a 12-fold increase in SF-1 protein
levels 48 h after transfection in relation to basal, as assessed by Western blotting.
Transfection of a plasmid bearing the G35E mutation in SF-1 cDNA sequence that impairs
SF-1 transactivation function was used as experimental control and led to overexpression
of the mutated protein to similar levels (data not shown). WT SF-1 overexpression led to
increased mRNA levels of well-established target genes CYP11A1 and STAR, assessed by
qRT-PCR, in comparison with control. Global gene expression was analyzed using
Affymetrix’s Human Gene 1.0ST arrays and principal component analysis (PCA) showed
distinct differences in the genomic profile resultant from WT SF-1 overexpression
compared with control samples (3 arrays each, PCA performed using Partek Genomics
Suite). B, Conversely, transient knockdown of SF-1 using SF-1–specific small hairpin RNA
(shRNA) resulted in approximately 55% decrease in SF-1 protein levels in comparison to
mismatch shRNA control at 48 h, reduced mRNA levels of STAR and CYP11A1, and
distinct array genomic profiles (five SF-1–specific shRNA arrays, four mismatch controls).
C, Aiming to identify novel SF-1 target genes in the adrenal, subsequent analysis focused
on those genes for which significant changes in expression levels were determined by
both SF-1 overexpression and knockdown (P  0.05, Benjamini-Hochberg correction for
multiple comparisons). A subset of seven genes up-regulated by SF-1 overexpression and
down-regulated by SF-1 knockdown included well-established SF-1 targets STAR and
CYP11A1 and five novel putative positively-regulated SF-1 target genes: visinin-like 1
(VSNL1); zinc finger, imprinted 2 (ZIM2); paternally expressed 3 (PEG3); sterol O-
acyltransferase 1 (SOAT1, also referred to as acyl-Coenzyme A:cholesterol acyltransferase
1); and metastasis suppressor 1 (MTSS1). ZIM2 (Entrez Gene ID 23619) and PEG3 (Entrez
Gene ID 5178) share the same locus and are represented by the same transcript cluster in
Affymetrix’s Human Gene 1.0ST arrays. D, SF-1 responsiveness of VSNL1, SOAT1, and
MTSS1 was confirmed in luciferase assays. Promoter constructs were generated based
upon in silico identification of SF-1–binding sites within the promoters of these genes
[VSNL1 (1.0 kb), SOAT1 (4.8 kb), and MTSS1 (1.7 kb)]. Dose-dependent activation of all
three promoters by wild-type SF-1 (WT) was seen. The amplitude of activation was similar
to that of a well-established SF-1 target gene, Cyp11a1 (data not shown). This activation
was diminished when the functionally-impaired G35E mutant SF-1 (Mut) was used
(, empty expression vector, followed by 50 and 100 ng per well of WT or Mut SF-1
expression vectors; data expressed as mean  SEM of at least three independent
experiments, each performed in triplicate).
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SF-1–dependent activation of these promoters linked to
luciferase (Fig. 1D).
Investigation of SOAT1 as a novel SF-1 target in
steroidogenesis
SF-1 regulation of SOAT1 was studied further, as this
gene is involved in cholesterol metabolism (Supplemental
Table4).Overexpressionandknockdownof SF-1 resulted
in up-regulation or down-regulation of SOAT1, respec-
tively, by qRT-PCR as well as microarray analysis (Fig.
2A). Furthermore, SOAT1 transcript levels were higher in
the fetal adrenal gland at a stage of active steroidogenesis
compared with control (Fig. 2B), and immunofluores-
cence showed strong SOAT1 signal in the developing de-
finitive zone of the fetal adrenal cortex (Fig. 2C).
A role for SOAT1 in human steroidogenesis
SOAT1 (also known as acyl-Coenzyme A:cholesterol
acyltransferase1andpreviously referred toasACAT) is an
important regulator of cholesteryl ester formation in the
adrenal gland (8). These stored pools of esterified choles-
terol can be readily liberated by the action of hormone-
sensitive lipase after ACTH stimulation and protect the
adrenal cells from the potentially damaging effects of free
cholesterol (Fig. 2D) (9). We hypothesized that impaired
SOAT1 activity could result in adrenal insufficiency in
humans through reduced cholesteryl ester reserves or
through toxic destruction of the adrenal cells during de-
velopment. Mutational analysis of the SOAT1 gene was
therefore undertaken in a cohort of 43 patients with ad-
renal insufficiency of unknown etiology (Supplemental
Methods). A novel heterozygous allelic variant in SOAT1
was identified in 4/84 alleles (4.8%) (c.872TC; p.I291T;
Ensembl GRCh37 transcript ENST00000367619) (Fig.
2E), but a similar variantoccurred in4/186 (2.2%)control
alleles (2  0.25). No potential disease-causing muta-
tionswere found in SOAT1, nor in another candidate gene
(C2CD2) identified from the SF-1 overexpression dataset
(Supplemental Data).
Discussion
In recent years, substantial progress has been made in our
understanding of the molecular basis of human adrenal
development and function. Nevertheless, a significant
proportion of cases of primary adrenal failure currently
remain unexplained (10). As several targets of SF-1 have
been shown to cause adrenal dysfunction in humans (11,
12), we developed a gene discovery strategy based on the
bidirectionalmanipulationof SF-1 in humanadrenal cells,
hypothesizing that novel SF-1 targets identified in this sys-
tem could be potential candidates for adrenal disorders.
Our strategy for SF-1 overexpression or knockdown
appeared robust at detectingpositively-regulated SF-1 tar-
gets, as CYP11A1 and STAR were two of seven genes
identified in the overlapping dataset. The five novel pu-
tative targets of SF-1 identified were as follows: visinin-
like 1 (VSNL1); zinc finger, imprinted 2 (ZIM2); pater-
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FIG. 2. A, Increased and decreased levels of SOAT1 mRNA 48 h after
SF-1 overexpression or knockdown, respectively, were confirmed by
qRT-PCR [data represented according to the 2CT method (5)]. B,
Expression of SOAT1 mRNA in human fetal adrenal tissue was assessed
by qRT-PCR. Results showed a marked increase in SOAT1 expression
from 6–7 to 8–9 wpc in comparison to control tissue (heart, 8 wpc),
reflecting active steroidogenesis in the fetal adrenal cortex. C,
Immunofluorescence confirmed strong expression of SOAT1 in the
outer layers of the human fetal adrenal cortex at 8 wpc but not in
overlying nonsteroidogenic capsule cells (DAPI, 4,6-diamidino-2-
phenylindol, was used to visualize nuclei). The omission of primary
antibody resulted in no signal (data not shown). D, Cartoon
representation of the actions of SOAT1 (HSL, hormone-sensitive lipase;
LIPA, lipase A). E, Cartoon representation of the SOAT1 locus at 1q25
and of the allelic variant identified.
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nally expressed 3 (PEG3); metastasis suppressor 1
(MTSS1); and, interestingly, sterol O-acyltransferase 1
(SOAT1).
Subsequent studies focused on SOAT1 (OMIM:
102642), a regulator of cholesteryl ester formation, be-
cause ACTH-induced mobilization of stored ester pools
viahormone-sensitive lipase is an importantmechanismto
generate free cholesterol for adrenal steroidogenesis (8, 9).
Furthermore, SOAT1 is essential for intracellular choles-
terol homeostasis, maintaining appropriate levels of un-
esterified cholesterol within cells for membrane stability
(13). We show here that SOAT1 is under SF-1 regulation
in adrenal cells in vitro and that SOAT1 expression in vivo
coincides spatially and chronologically with active ste-
roidogenesis in the human fetal adrenal cortex.
Naturally-occurring (ald, AKR, Soat1ald) or targeted
disruptionof Soat1 inmice leads tomarked lipid depletion
in the adrenal cortex and variable abnormalities of cho-
lesterol esterification and corticosterone synthesis (14,
15). However, substantial interspecies differences exist in
the mechanisms of cholesterol generation as well as in the
expression and activity of this enzyme (16, 17), as recently
demonstrated by differences in antiatherogenic effects
elicited by SOAT1 inhibitors between species (18). We
therefore hypothesized that impaired SOAT1 activity
could result in adrenal insufficiency in humans, either
through reduced cholesteryl ester reserves or through
toxic destruction of the adrenal cells during development.
Although SOAT1 changes are not a common cause of
adrenal dysfunction in this heterogeneous cohort of pa-
tients studied, it is possible that SOAT1 allelic variants
may explain less severe cases of adrenal dysfunction or
have more prominent effects in systems more susceptible
to subtle changes in steroidogenic output such as the de-
veloping testis.
In conclusion, our reverse discovery approach based on
the bidirectional manipulation of SF-1 in adrenal cells led
to the identificationofnovel SF-1 targets in this systemand
defined SOAT1 as an important factor in human adrenal
steroidogenesis.We hypothesize that SF-1–dependent up-
regulationof SOAT1 is important formaintaining readily-
releasable pools of cholesterol esters needed at times of
active steroidogenesis or during episodes of recurrent
stress.
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